David D Pool

US Patent:

20160339052, Nov 24, 2016

Filed:

Mar 21, 2016

Appl. No.:

15/076513

Inventors:

- San Diego CA, US
David EISENBUD - San Diego CA, US
Scott BANNAN - San Diego CA, US
Grove MATSUOKA - San Diego CA, US
David POOL - San Diego CA, US
Tracey SUNDERLAND - San Diego CA, US
Bradford DUFT - San Diego CA, US

International Classification:

A61K 31/7088
A61K 9/00
A61B 5/107
A61K 9/06
A61K 9/70
A61B 5/00
C12N 15/113
A61K 47/10

Abstract:

This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

US Patent:

20160264977, Sep 15, 2016

Filed:

Mar 15, 2014

Appl. No.:

14/777458

Inventors:

Bradford James DUFT - San Diego CA, US
- San Diego, CA, US
Scott BANNAN - Auckland, NZ
David POOL - San Diego CA, US
Grove MATSUOKA - San Diego CA, US
Tracey SUNDERLAND - Auckland, NZ

Assignee:

CoDa Therapeutics, Inc. - San Diego CA

International Classification:

C12N 15/113
A61K 47/10
A61B 5/00
A61K 47/38
A61K 31/7105
A61K 9/00
A61K 9/06

Abstract:

This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

US Patent:

20140275209, Sep 18, 2014

Filed:

Mar 15, 2013

Appl. No.:

13/844762

Inventors:

- San Diego CA, US
David Eisenbud - San Diego CA, US
Scott Bannan - San Diego CA, US
David Pool - San Diego CA, US
Grove Matsuoka - San Diego CA, US
Tracey Sunderland - San Diego CA, US
Bradford Duft - San Diego CA, US

Assignee:

CoDa THERAPEUTICS, INC. - San Diego CA

International Classification:

C12N 15/113

US Classification:

514 44 A, 514 44 R

Abstract:

This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

US Patent:

20140275218, Sep 18, 2014

Filed:

Mar 15, 2014

Appl. No.:

14/214922

Inventors:

- San Diego CA, US
David EISENBUD - San Diego CA, US
Scott BANNAN - San Diego CA, US
David POOL - San Diego CA, US
Grove MATSUOKA - San Diego CA, US
Tracey SUNDERLAND - San Diego CA, US
Bradford DUFT - San Diego CA, US

Assignee:

CoDa Therapeutics, Inc. - San Diego CA

International Classification:

C07K 14/47
A61B 5/00
A61B 5/107

US Classification:

514 44 A, 514 44 R, 536 235, 600587

Abstract:

This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.